State Street Corp Purchases 512,682 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST)

State Street Corp boosted its position in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 52.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,496,739 shares of the company’s stock after purchasing an additional 512,682 shares during the quarter. State Street Corp owned about 1.64% of Aquestive Therapeutics worth $7,454,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. Verition Fund Management LLC acquired a new stake in shares of Aquestive Therapeutics during the 3rd quarter worth approximately $995,000. Blue Owl Capital Holdings LP grew its holdings in Aquestive Therapeutics by 30.3% during the 2nd quarter. Blue Owl Capital Holdings LP now owns 1,140,000 shares of the company’s stock worth $2,964,000 after acquiring an additional 265,000 shares during the period. Bank of New York Mellon Corp bought a new stake in shares of Aquestive Therapeutics during the 2nd quarter valued at $594,000. Chartwell Investment Partners LLC acquired a new position in shares of Aquestive Therapeutics in the 3rd quarter valued at $535,000. Finally, BNP Paribas Financial Markets boosted its position in shares of Aquestive Therapeutics by 252.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 18,826 shares of the company’s stock worth $94,000 after purchasing an additional 13,481 shares during the last quarter. 32.45% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Leerink Partners increased their target price on Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. Cantor Fitzgerald began coverage on shares of Aquestive Therapeutics in a research report on Tuesday, December 17th. They issued an “overweight” rating and a $17.00 price target on the stock. JMP Securities restated a “market outperform” rating and set a $9.00 price objective on shares of Aquestive Therapeutics in a report on Tuesday, October 8th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a report on Friday, December 20th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $11.00.

Aquestive Therapeutics Stock Performance

Shares of AQST opened at $3.52 on Friday. The stock has a 50 day simple moving average of $4.61 and a 200 day simple moving average of $4.09. Aquestive Therapeutics, Inc. has a 52-week low of $1.95 and a 52-week high of $6.23. The firm has a market capitalization of $320.95 million, a PE ratio of -7.82 and a beta of 2.62.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings results on Monday, November 4th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The firm had revenue of $13.54 million for the quarter, compared to the consensus estimate of $12.69 million. During the same period in the previous year, the business earned ($0.03) EPS. Equities research analysts predict that Aquestive Therapeutics, Inc. will post -0.47 EPS for the current fiscal year.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.